NEW YORK, December 30, 2025, 12:55 ET — Regular session
- AbbVie shares fell about 0.8% in midday trading, lagging the broader market.
- Investors awaited Federal Reserve minutes amid thin year-end liquidity.
- Traders are watching rate signals and the next earnings window for direction.
AbbVie Inc. shares fell 0.8% to $228.89 in midday trading on Tuesday. The stock ranged between $228.66 and $231.55 after opening at $230.77, with volume near 795,000 shares.
The move came as Wall Street traded with little direction in holiday-thinned turnover, leaving the Dow down 0.24%, the S&P 500 off 0.09% and the Nasdaq lower by 0.07% around midday, Reuters reported. Investors were awaiting minutes from the Federal Reserve’s Dec. 9-10 meeting, when it cut rates by 25 basis points — a quarter of a percentage point — but signaled caution on further reductions. “It’s just a healthy rebalancing of allocations more so than an emotionally driven sell-off,” said Mark Hackett, chief market strategist at Nationwide. Reuters
Defensive healthcare also lagged, with the Health Care Select Sector SPDR ETF down about 0.2% while the SPDR S&P 500 ETF was roughly flat. AbbVie’s decline left it trailing both benchmarks.
Other large drugmakers were softer as well. Merck was down about 0.5%, Johnson & Johnson slipped roughly 0.2% and Amgen fell about 0.8%.
Rate expectations can matter for AbbVie because investors often price dividend payers against Treasury yields. When yields rise, bonds can look more attractive relative to steady-income stocks; when yields fall, defensives can regain favor.
AbbVie sells drugs across immunology, oncology, aesthetics, neuroscience and eye care, according to a Reuters company profile. Its product lineup includes Imbruvica in oncology and Botox Therapeutic in neuroscience, among other medicines.
Longer term, investors have stayed focused on the company’s post-Humira transition. Humira faced biosimilar competition after losing U.S. exclusivity in 2023, pushing attention toward newer immunology drugs such as Skyrizi and Rinvoq.
In the near term, macro headlines have taken a bigger share of the driver’s seat. The tone of the Fed minutes can shift expectations for where policy is headed in 2026, and that can quickly reshuffle sector leadership in low-liquidity sessions.
The next company milestone on many market calendars is the quarterly report. Investing.com lists Feb. 4, 2026 as AbbVie’s next earnings date.
That report is likely to be a key checkpoint for investors looking for updated guidance and evidence that newer drugs are offsetting declines in mature products. Any commentary on pricing and competitive dynamics will also be closely read.
For now, AbbVie’s mid-session slide fits the broader tone of cautious positioning into the Fed release, with healthcare moving slightly out of step with a near-flat market.
